Long-term neurodevelopmental consequences of intrauterine exposure to lithium and antipsychotics: a systematic review and meta-analysis

Lithium and antipsychotics are often prescribed to treat bipolar disorder or psychotic disorders in women of childbearing age. Little is known about the consequences of these medications during pregnancy for the developing child. The objective of this article is to systematically review findings from preclinical and clinical studies that have examined the neurodevelopmental consequences of intrauterine exposure to lithium and antipsychotics. A systematic search was performed in Embase, Medline, Web of Science, PsychINFO, Cochrane, and Google Scholar. Clinical and experimental studies were selected if they investigated neurodevelopment of offspring exposed to lithium or antipsychotics during gestation. Quality of clinical and preclinical studies was assessed by the Newcastle–Ottawa Scale and the SYRCLE’s risk of Bias tool, respectively. In total, 73 studies were selected for qualitative synthesis and three studies were selected for quantitative synthesis. Of preclinical studies, 93% found one or more adverse effects of prenatal exposure to antipsychotics or lithium on neurodevelopment or behaviour. Only three clinical cohort studies have investigated the consequences of lithium exposure, all of which reported normal development. In 66% of clinical studies regarding antipsychotic exposure, a transient delay in neurodevelopment was observed. The relative risk for neuromotor deficits after in utero exposure to antipsychotics was estimated to be 1.63 (95% CI 1.22–2.19; I2 = 0%). Preclinical studies suggest long-term adverse neurodevelopmental consequences of intrauterine exposure to either lithium or antipsychotics. However, there is a lack of high-quality clinical studies. Interpretation is difficult, since most studies have compared exposed children with their peers from the unaffected population, which did not allow correction for potential influences regarding genetic predisposition or parental psychiatric illness

Fear odor facilitates the detection of fear expressions over other negative expressions

In a double-blind experiment, participants were exposed to facial images of anger, disgust, fear, and neutral expressions under 2 body odor conditions: fear and neutral sweat. They had to indicate the valence of the gradually emerging facial image. Two alternative hypotheses were tested, namely a "general negative evaluative state" hypothesis and a "discrete emotion" hypothesis. These hypotheses suggest 2 distinctive data patterns for muscle activation and classification speed of facial expressions. The pattern of results that would support a "discrete emotions perspective" would be expected to reveal significantly increased activity in the medial frontalis (eyebrow raiser) and corrugator supercilii (frown) muscles associated with fear, and significantly decreased reaction times (RTs) to "only" fear faces in the fear odor condition. Conversely, a pattern of results characterized by only a significantly increased corrugator supercilii activity together with decreased RTs for fear, disgust, and anger faces in the fear odor condition would support an interpretation in line with a general negative evaluative state perspective. The data support the discrete emotion account for facial affect perception primed with fear odor. This study provides a first demonstration of perception of discrete negative facial expressions using olfactory priming

Corrigendum : Fear odor facilitates the detection of fear expressions over other negative expressions [Chem. Senses (2018)] DOI: 10.1093/chemse/bjy029

This is a correction notice for article bjy029 (DOI: https://doi.org/10.1093/chemse/bjy029), published on 22 May 2018. Due to an error, the incorrect images were used for figures 2 and 3. These figures have now been corrected in the published article

Corrigendum: Fear odor facilitates the detection of fear expressions over other negative expressions [Chem. Senses (2018)] DOI: 10.1093/chemse/bjy029

This is a correction notice for article bjy029 (DOI: https://doi.org/10.1093/chemse/bjy029), published on 22 May 2018. Due to an error, the incorrect images were used for figures 2 and 3. These figures have now been corrected in the published article

Clinical evaluation of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy for advanced urothelial cancer

進行性尿路上皮癌27例に対してM-VAC療法を施行した。CR 2例(15.4%)を含め奏効率は, 44.4%と, 導入療法としては良好な成績であった。しかし, 再発および再燃が高率に認められ, 維持療法の確立が必要と考えられたM-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy was performed on 27 patients with advanced urothelial cancer. The patients included 20 with bladder cancer, 4 with upper urinary tract cancer and 3 with both lesions. Complete response (CR) was observed in 2 (7.4 +/- 9.9%) patients and partial response (PR) in 10 (37.0 +/- 18.2%) patients after the treatment, i.e., the overall objective response rate was 44.4 +/- 18.7%. The rate of relapse or recurrence in the patients with CR and PR was 100% and 90.0%, respectively. The mean duration of the response was 18.5 +/- 13.4 months and 10.7 +/- 10.9 months for CR and PR, respectively. The overall survival rate after one year was 30.2%. Bone marrow suppression was the most serious side effect. The white blood cell count became below 1, 000/microliters in 10 patients (36.7%). Among them, 4 patients suffered from sepsis. In conclusion, M-VAC chemotherapy was effective for induction therapy against advanced urothelial cancer, although the effective duration was short. Further maintenance therapy should be established